EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Antibiotice Ia (ATB) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Antibiotice Ia RON 1.31, price RON 1.83, upside -28.6%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · RO · ISIN ROATBIACNOR9

AI Thin data Sep 24, 2026

Antibiotice Ia

ATB · RO

Weak valuationQuality is weak on top of the rich price.

!Fair value 1.31 RON · Overvalued (−29%)
!Quality 40/100
!Expensive Growth (revenue 5y +13.6 %/yr)
!Thin margins · 5.0% net margin (TTM)
!Low debt · negative free cash flow
·1.96% dividend yield
!Trails peers (5/14)
!Narrow moat 33/100
!Evidence only low, so the estimate is less certain
!Weak on past: 14 out of 100
Watch Antibiotice Ia for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

3.36 RON 0.4689 RON Fair Value 1.31 RON Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 0.4689 RON – 3.36 RON · fair‑value band 0.9800 RON – 1.64 RON · the 1.83 RON price screens above the 1.31 RON fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Antibiotice Ia in your weekly email

Every Wednesday you see whether Antibiotice Ia is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Antibiotice S.A. produces and sells medicinal products in Romania and internationally.

Show more

Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparations; generic non-prescription medicines, including food supplements, cosmetics, and medical devices; active substances; biofertilizers; biocides for disinfecting surfaces and hands; and veterinary medicines. Its products are available in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, pessaries, and suppositories. It offers active pharmaceutical ingredients. The company exports its products to approximately 70 countries. Antibiotice S.A. was founded in 1955 and is headquartered in Iasi, Romania.

Stock analysis

Antibiotice Ia (ATB) currently trades at 1.83 RON, while our model-based Fair Value estimate is 1.31 RON, implying the stock looks roughly 40.0% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 1.47 RON per share, and 2 of the 16 models we run sit above the 1.83 RON price.

Bear case: the Dividend Discount group reads lowest at 0.2600 RON, and 14 of the 16 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.9800 RON (bear) to 1.64 RON (bull), the price of 1.83 RON sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Antibiotice Ia reported revenue of 645M RON in FY2025 versus 366M RON in FY2021, a compound +15.2%/yr. Reported net income was 51.8M RON in FY2025, compounding +14.7%/yr from FY2021.

Key figures

Market cap 1.4B RON (≈ $294M) · P/E ratio 36.7 · P/S ratio 2.94 · EPS (TTM) 0.0500 RON · Dividend yield 2.0% · Net margin 8.0% · Return on equity 3.4% · Return on assets (EBIT) 6.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −29%, ATB screens richer than that median.

Fair Value models

Bear 0.9800 RON Fair Value 1.31 RON Bull 1.64 RON
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (0.0138 RON per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income 0.9700 RON 0.9500 RON 0.8200 RON 76
ROIC Compounder 0.3300 RON 0.3900 RON 0.4400 RON 72
EPV 0.3300 RON 0.3900 RON 0.4400 RON 71
All 16 models by family
Earnings-Based
Graham-Dodd 0.5200 RON 2.37 RON 3.26 RON 64
Lynch FV 0.6200 RON 0.8900 RON 1.15 RON 61
PEG = 1.0 0.6200 RON 0.8900 RON 1.15 RON 57
EPV 0.3300 RON 0.3900 RON 0.4400 RON 71
Dividend Discount
Gordon GGM 0.1700 RON 0.2800 RON 0.3600 RON 68
DDM Multi-Stage 0.1700 RON 0.2600 RON 0.3000 RON 67
Multiples
P/E Multiple 1.27 RON 1.70 RON 2.12 RON 63
P/S Multiple 0.9800 RON 1.31 RON 1.64 RON 58
P/B Multiple 0.9800 RON 1.31 RON 1.64 RON 55
EV/EBIT 0.9800 RON 1.36 RON 1.75 RON 66
EV/EBITDA 1.60 RON 2.19 RON 2.79 RON 67
EV/Revenue 0.6400 RON 1.00 RON 1.35 RON 53
Asset-Based
NCAV (Graham) 0.6900 RON 0.9300 RON 1.39 RON 54
Economic Profit
Residual Income 0.9700 RON 0.9500 RON 0.8200 RON 76
ROIC Compounder 0.3300 RON 0.3900 RON 0.4400 RON 72
Growth Earnings
Growth-Adj P/E 1.03 RON 1.47 RON 1.91 RON 67

Open the full fair value analysis →

Notify me when ATB reaches fair value

Put ATB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 40/100

Of which business quality 44 · Market factors (momentum, volatility) 39

Profitability 38
Margins and returns on capital today
Quality Growth 16
Are margins and returns improving?
Cashflow 27
Earnings quality: real cash, not paper profit
Fin. Strength 74
Balance sheet, leverage, solvency risk
Investment 15
Disciplined investing over empire-building
Low Volatility 89
Calm price path (market factor)
Momentum 26
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 45/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−4.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+14.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.9%
Dividend (yield on the price)2.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 10%

ATB screens 40% overvalued. Compare with Merck KGaA →

Compare Antibiotice Ia with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks

Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −30% · Below median
Profitability
Return on equity (TTM) 3% · Below median
Return on assets 2% · Below median
Net margin (TTM) 5% · Below median
Operating margin (TTM) 10% · Above median
Growth and dividend
Revenue growth −13% · Bottom 25%
Dividend yield (TTM) 2.0% · Above median
Balance sheet
Debt / equity 0.15× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 36.7× · Pricier than median
P/B 0.31× · Cheapest 25%
P/S (TTM) 0.46× · Cheapest 25%
EV/EBITDA 4.0× · Cheapest 25%
PEG 3.89× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)0 · sector 20
PAST (return on equity)14 · sector 27
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)39 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.01 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Antibiotice Ia · Fair Value
1.31 RON −40%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Antibiotice Ia Fair Value". https://www.fairvalue-calculator.com/stock/ATB

Frequently asked questions

Is Antibiotice Ia (ATB) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1.31 RON versus a price of 1.83 RON, about −29% upside (overvalued).
What is the fair value of ATB?
Our model-based fair value for Antibiotice Ia is 1.31 RON (as of Sep 24, 2026), built from audited fundamentals. The current price: 1.83 RON.
What is the quality score of ATB?
Antibiotice Ia has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Antibiotice Ia (ATB)?
Our model-based price target is the fair value of 1.31 RON (as of Sep 24, 2026) from 16 valuation models. Cautious scenario 0.9800 RON, optimistic scenario 1.64 RON. It is a calculation from audited fundamentals, not an analyst target.
What is the Antibiotice Ia stock forecast for 2026?
Our models put fair value at 1.31 RON, about −29% upside versus a price of 1.83 RON (overvalued). Cautious scenario 0.9800 RON, optimistic scenario 1.64 RON. The calculation is refreshed regularly with new filings.
What is the revenue of Antibiotice Ia (ATB)?
Antibiotice Ia reported trailing-twelve-month revenue of about 639M RON (latest available figure, as of Sep 24, 2026).
Does Antibiotice Ia pay a dividend?
Antibiotice Ia currently shows a dividend yield of about 1.96% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Antibiotice Ia (ATB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Antibiotice Ia it is 1.31 RON per share (as of Sep 24, 2026), against a price of 1.83 RON. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Antibiotice Ia stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ATB trades above its calculated fair value: price 1.83 RON, fair value 1.31 RON, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATB?
No. The price is what the market pays today (1.83 RON); the fair value is what the company's own numbers justify (1.31 RON). For Antibiotice Ia the two are 0.5240 RON per share apart. That gap is exactly why we show both numbers side by side.
How much is Antibiotice Ia worth?
The market values Antibiotice Ia at about 1.4B RON (market capitalisation, as of Sep 24, 2026). Per share that is 1.83 RON; our models calculate a fair value of 1.31 RON per share.
What do the bullish and bearish scenarios say about ATB?
Our models span a range for Antibiotice Ia: cautious scenario 0.9800 RON, base 1.31 RON, optimistic 1.64 RON per share (as of Sep 24, 2026, price 1.83 RON). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ATB?
Antibiotice Ia trades at a price-to-earnings ratio of 36.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.31 RON is built from several models across several years. Other multiples: PEG 3.9, P/B 0.3, P/S 0.5, EV/EBITDA 4.0.
What is the PEG ratio of ATB?
The PEG ratio of Antibiotice Ia is 3.89 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Antibiotice Ia (ATB)?
Balance-sheet figures for Antibiotice Ia (as of Sep 24, 2026): return on equity 3.4%, debt of 0.15 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is ATB from its 52-week high?
Antibiotice Ia trades at 1.83 RON, about 29% below its 52-week high of 2.60 RON and 3% above the low of 1.77 RON (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.31 RON is for.
Which stocks are comparable to Antibiotice Ia?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Antibiotice Ia stock attractive at the current price?
The data as of Sep 24, 2026: price 1.83 RON, calculated fair value 1.31 RON (−29%), Quality Score 40/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATB calculated?
We run Antibiotice Ia through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.31 RON, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Antibiotice Ia itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Antibiotice Ia (ATB)?
The closing price on Sep 24, 2026 was 1.83 RON. Our model-based fair value is 1.31 RON, about −29% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Antibiotice Ia right now?
The price sits above even our optimistic bull case (1.64 RON). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Antibiotice Ia

How large is the market capitalisation of Antibiotice Ia (ATB)?
The market capitalisation of Antibiotice Ia is 1.4B RON (≈ $294M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Antibiotice Ia (ATB)?
The price-to-sales ratio of Antibiotice Ia is 2.94 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Antibiotice Ia (ATB)?
Earnings per share at Antibiotice Ia are 0.0500 RON (price ÷ EPS = P/E 36.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Antibiotice Ia (ATB)?
The dividend yield of Antibiotice Ia is 2.0% (payout 72.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Antibiotice Ia (ATB)?
The net margin of Antibiotice Ia is 8.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Antibiotice Ia (ATB)?
The return on equity (ROE) of Antibiotice Ia is 3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Antibiotice Ia (ATB)?
On an EBIT basis the return on assets of Antibiotice Ia is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Antibiotice Ia (ATB)?
The operating margin of Antibiotice Ia is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Antibiotice Ia (ATB)?
Revenue at Antibiotice Ia is growing −12.9% versus a year earlier (3y avg +10.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Antibiotice Ia (ATB)?
Earnings per share at Antibiotice Ia are growing −61.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Antibiotice Ia (ATB) generate?
The free cash flow of Antibiotice Ia is −70.2M RON (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Antibiotice Ia (ATB) carry?
The net debt of Antibiotice Ia is 224M RON (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Antibiotice Ia in the live analysis

One click puts Antibiotice Ia on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.